Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Psoriatic Arthritis Treatment & Management

  • Author: Anwar Al Hammadi, MD, FRCPC; Chief Editor: Herbert S Diamond, MD  more...
 
Updated: Jan 21, 2016
 

Approach Considerations

The treatment of psoriatic arthritis is directed at controlling the inflammatory process. Although no clear correlation exists between joint inflammation and the skin in every patient, the skin and joint aspects of the disease often must be treated simultaneously.

EULAR recommendations

Based on evidence from systematic literature reviews and expert opinion, the European League Against Rheumatism (EULAR) developed 10 treatment recommendations, 5 overarching principles, and a research agenda for psoriatic arthritis. The recommendations are as follows[49] :

  • NSAIDs can be administered for the relief of musculoskeletal signs and symptoms
  • Treatment with disease-modifying agents—eg, methotrexate, sulfasalazine, and leflunomide—should be considered at an early stage for patients with active disease
  • If a patient with active psoriatic arthritis also has clinically relevant psoriasis, preference should be given to treatment with methotrexate or other disease-modifying drugs that are also effective against psoriasis
  • Adjunctive treatment with local corticosteroid injections should be considered; cautious use of systemic steroids, if administered at the lowest effective dose, can also be considered
  • If active psoriatic arthritis fails to adequately respond to 1 or more synthetic, disease-modifying antirheumatic medications (eg, methotrexate), TNF-inhibitor therapy should be employed
  • TNF-inhibitor therapy should also be considered if a patient with active enthesitis and/or dactylitis does not show sufficient response to NSAIDs or local steroid injections
  • TNF-inhibitor therapy should be considered if a patient has active, predominantly axial disease that does not respond sufficiently to NSAIDs
  • Exceptional use of TNF-inhibitor therapy may be considered if a very active patient is disease-modifying ̶ treatment naïve
  • If a TNF inhibitor produces an inadequate response, consideration should be given to replacing it with another TNF inhibitor
  • If adjustments are made in a patient’s therapy, then comorbidities, safety concerns, and other considerations beyond the psoriatic arthritis itself should be factored into the change

British Society of Rheumatology recommendations

The British Society of Rheumatology (BSR) issued guidelines for the treatment of adult psoriatic arthritis with biologic agents (particularly anti-TNF] therapy).[50, 51] The BSR recommends considering anti-TNF treatment in patients with any of the following[50] :

  • Active peripheral arthritis refractory to at least 2 conventional disease-modifying antirheumatic drugs (DMARDs)
  • Peripheral disease refractory to 1 DMARD plus the presence of adverse prognostic factors
  • Severe persistent oligoarthritis that is affecting well-being and refractory to at least 2 DMARDs and intra-articular therapy
  • Axial disease

The BSR recommendations on response assessment include the following[50] :

  • Use the psoriatic arthritis response criteria as the clinical response criteria for peripheral disease
  • Use the psoriasis area severity index score for significant skin psoriasis

Safety recommendations include the following[50] :

  • Do not start or continue anti-TNF therapy in patients with serious active infection; use caution in those at high risk of infection
  • Screen all patients for infection with mycobacteria, human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) before starting anti-TNF therapy
  • Consider prophylactic vaccination for tuberculosis and HBV in high-risk patients before initiating anti-TNF therapy
  • In patients with HIV, HBV, or HCV, initiate anti-TNF therapy only in those with well-controlled disease and appropriate monitoring; appropriate antiviral therapy for patients with HBV is also important
  • Avoid anti-TNF treatment in patients with a current or previous history of malignancy, unless there is a high likelihood of cure or the malignancy was diagnosed and treated more than 10 years ago
  • Regularly screen for skin cancers in patients who are receiving anti-TNF therapy and who have a history of current or previous malignancy
  • Discontinue anti-TNF therapy prior to pregnancy; restart anti-TNF treatment following the end of lactation or delivery if the mother is not breastfeeding
  • Consider an alternative anti-TNF agent in patients whose condition is refractory to a first anti-TNF agent; assess the treatment response as for the first agent
Next

Pharmacotherapy

Medical treatment regimens include the use of NSAIDs and disease-modifying antirheumatic drugs (DMARDs). Although traditional therapy has consisted of NSAIDs and local corticosteroid injections, with DMARDs being reserved for NSAID-resistant cases, the finding that 40% of patients may develop erosive and deforming arthritis suggests that early, more aggressive treatment with DMARDs may be warranted.

DMARDs include methotrexate, sulfasalazine, cyclosporine, and leflunomide, as well as biologic agents (eg, anti–TNF-alpha medications, IL-12, IL-17, or -23 monoclonal antibodies).[3, 52, 53]

In September 2013, the FDA and the European Union approved ustekinumab, an interleukin-12/23 inhibitor, for the treatment of active psoriatic arthritis in adults who have not responded adequately to previous treatment with nonbiologic DMARDs.[54] The drug was already approved in Europe and the United States for treatment of moderate to severe psoriatic plaques in adults.

Approval was based on 2 randomized, double-blind, placebo-controlled trials in 927 patients with active psoriatic arthritis who had at least 5 tender and 5 swollen joints and C-reactive protein levels of 0.3 mg/dL or higher despite previous conventional therapy.[54] At week 24, 42% of patients receiving ustekinumab 45 mg and 50% of those receiving 90 mg achieved at least 20% improvement; at 52 weeks, this response was found to have been sustained. Treatment with ustekinumab also improved dactylitis, enthesitis, and skin component.[54]

In the same month, the FDA also approved the TNF inhibitor certolizumab pegol (Cimzia) for the treatment of active psoriatic arthritis in adults.[55] Approval was based on an ongoing, randomized, double-blind, placebo-controlled trial in 409 patients with active and progressive adult-onset psoriatic arthritis in which certolizumab-treated patients were significantly more likely to meet American College of Rheumatology 20%, 50%, and 70% response criteria by week 12 than placebo-treated patients. Certolizumab reduced radiographic progression and improved skin manifestations.[55]

Apremilast (Otezla), was approved in March 2014 by the FDA for treatment of active psoriatic arthritis (PsA). It is a phosphodiesterase-4 (PDE4) inhibitor that is specific for cAMP, resulting in increased intracellular cAMP levels. Apremilast was evaluated in nearly 1500 patients with PsA. Patients received apremilast 30 mg PO BID plus concomitant therapy with at least 1 DMARD, methotrexate, leflunomide, oral corticosteroids, or NSAIDs. At week 6, improvement (ie, ACR20) was observed in 32-41% of patients. This was a statistically significant difference compared with placebo (p < 0.05).[56, 57, 58, 59]

Secukinumab (Cosentyx) is a human IgG1 monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin 17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab was approved by the FDA for adults with active psoriatic arthritis in January 2016.

Approval of secukinumab was based on the FUTURE 1 and 2 phase 3 trials. In the FUTURE 1 trial (n=606), the American College of Rheumatology 20 (ACR20) response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%) (P<0.001 for both comparisons with placebo).[52] In FUTURE 2, patients were randomly assigned to receive secukinumab 300 mg (n=100), 150 mg (n=100), 75 mg (n=99), or placebo (n=98). A significantly higher proportion of patients achieved an ACR20 at week 24 with secukinumab doses of 300 mg (54%; P<0.0001) and 150 mg (51%; P<0.0001) compared with placebo (15%).[53]

In patients with severe skin inflammation, medications such as methotrexate, retinoic-acid derivatives, and psoralen plus ultraviolet (UV) light should be considered. These agents have been shown to work on skin and joint manifestations.

Intolerance to methotrexate was observed in 14.3% of patients with PsA in a cross-sectional study (n=291), as measured with the Methotrexate Intolerance Severity Score (MISS). GI symptoms, including nausea, abdominal pain, and vomiting, occurred during methotrexate treatment in 123 patients (42.3%); behavioral symptoms, including restlessness and irritability, were also common. Methotrexate intolerance was more common with parenteral (20.6%) than oral (6.2%) administration.[60, 61]

Intra-articular injection of entheses or single inflamed joints with corticosteroids may be particularly effective in some patients. Use disease-modifying drugs in individuals whose arthritis is persistent. If the skin disease is well controlled with topical medication, the joint disease can be treated with a variety of second-line or cytotoxic drugs. Intramuscular administration of gold has been used in the past but has been supplanted by newer DMARDs.

In a study completed by the Psoriatic Arthritis Study Group, patients with psoriasis and psoriatic arthritis who were receiving stable doses of methotrexate were found to benefit from the addition of 1 or more courses of intramuscular alefacept, a T-cell inhibitor via a human lymphocyte function–associated antigen 3 (LFA-3) Fc fusion protein that blocks the interaction between CD2 on T cells and LFA-3 on antigen-presenting cells. Further benefit in psoriatic arthritis was apparent after a second course of alefacept, and no additional toxicity was observed.[2]

Sulfasalazine and cyclosporine are 2 second-line DMARDs that have received particular attention in the management of psoriatic arthritis. Although these drugs may control the acute inflammation in persons with psoriatic arthritis, they have not been helpful in arresting the progression of clinical and radiologic damage. Thus, the disease must be treated earlier or better drugs are necessary, to prevent the damage that may ensue as a result of psoriatic arthritis.

Cyclosporine appears to be an effective agent for the treatment of psoriasis and psoriatic arthritis. The major concern with this drug is its toxicity, especially its nephrotoxicity, and hypertension.

Combination therapy (eg, methotrexate/sulfasalazine, methotrexate/cyclosporine) may be more efficacious in some patients.[62]

Several other agents have been tried in persons with psoriatic arthritis, including vitamin D-3, bromocriptine, peptide T, and fish oils, but their efficacy remains to be proven.

Antimalarials, particularly hydroxychloroquine, are usually avoided in patients with psoriasis for fear of precipitating exfoliative dermatitis or exacerbating psoriasis. However, 2 studies showed that these reactions did not occur in patients who were treated with hydroxychloroquine; therefore, this drug is occasionally used to treat psoriatic arthritis.

Systemic corticosteroids are usually avoided because of possible rebound of the skin disease upon withdrawal.

Previous
Next

Physical Therapy

The rehabilitation treatment program for patients with psoriatic arthritis should be individualized and should be started early in the disease process. Such a program should consider the use of the following:

  • Rest: Local and systemic
  • Exercise: Passive, active, stretching, strengthening, and endurance
  • Modalities: Heat and cold treatments can temporarily relieve pain and reduce joint swelling; such treatments include soaking in a warm tub or placing a warm compress or cold pack on the painful joint
  • Orthotics: Upper and lower extremities, spinal
  • Assistive devices for gait and adaptive devices for self-care tasks: Including possible modifications to homes and automobiles
  • Education about the disease, energy conservation techniques, and joint protection
  • Possible vocational readjustments

With regard to the first item above, prolonged rest should be avoided to prevent the deleterious effects of immobility. In a very few people, psoriatic arthritis may cause extreme fatigue.

Acute phase

Encourage rest as indicated. Splints may be used for rest and pain relief, especially for the hands, wrists, knees, or ankles. Cold modalities should be used to decrease inflammation and assist with pain relief. Joints should not be moved beyond the limit of pain; passive movements should be limited at this time. Education should be completed during this phase, with topics including the disease itself, the importance of rest, the exercise program, joint protection, energy conservation, and weight loss, if appropriate.

Subacute and long-term phase

Isometric exercises are begun, with progression to active movement. Gradual range-of-motion (ROM) exercises include passive and active exercises; areas with subluxation should not be forced passively. Heating modalities, including moist heat packs, paraffin wax, diathermy, and ultrasound, can be used to decrease pain; heat therapy should be administered just prior to the performance of ROM exercises.

Institute gait activities, with the patient bearing weight as tolerated, with or without an assistive device. Gentle stretching should be gradually introduced. If pain persists beyond 2 hours after therapies, then the intensity should be decreased. If a joint is swollen, then no resistive exercises should be performed through full ROM.

For patients with axial spine involvement, spine extension exercises help with flexibility and strength. ROM exercises should be performed, but not in patients with increased pain.

If the patient has sausage toes, extra-depth shoes with a high toe box should be considered to protect the foot. With pain in the toes, such shoes should have a rocker-bottom modification to alleviate forces during the toe-off phase in the gait cycle. The patient may also benefit from arch supports if plantar fascitis is a problem.

Previous
Next

Synovectomy and Arthroplasty

Currently, no prospective studies are addressing surgical intervention in patients with psoriatic arthritis. Patients in severe pain or with significant contractures may be referred for possible surgical intervention. Treatment should be aimed at pain relief or increasing the patient's function.

Arthroscopic synovectomy has been effective in treating severe, chronic, monoarticular synovitis. Because of an enhanced tendency for patients to develop fibrosis in association with this therapy, anti-inflammatory and physical therapy measures aimed at improving ROM are important adjuncts to this intervention.

Joint replacement and forms of reconstructive therapy are occasionally necessary. Hip and knee joint replacements have been successful, for the most part, in patients with psoriatic arthritis. Arthrodesis and arthroplasty have also been used on joints, such as the proximal interphalangeal joint of the thumb. The wrist often spontaneously fuses, and this may relieve the patient's pain without surgical intervention.

Because of the diffuse soft-tissue involvement that is associated with psoriatic arthritis, high rates of recurrence of joint contractures have been noted after surgical release, especially in the hand.

For arthritis mutilans, surgical intervention is usually directed toward salvage of the hand. Combinations of arthrodesis, arthroplasty, and bone grafts to lengthen the digits may be used. The goal is to maintain the pinch mechanism of the thumb and the first 2 fingers.

Previous
Next

Consultations

If the patient's physiatrist feels uncomfortable with prescribing medications for psoriatic arthritis, referral to a rheumatologist with more experience with these agents may be advisable. The physiatrist may then concentrate on functional restoration of the patient. Referral to a surgeon should be considered for appropriate patients.

with juvenile psoriatic arthritis should be examined by an ophthalmologist annually to check for the several forms of eye inflammation usually associated with various forms of juvenile arthritis.

Given the complexity of DMARD therapy, patients with psoriatic arthritis should be followed simultaneously by a rheumatologist and physiatrist. In addition, consultation with an orthopedic surgeon is warranted for individuals who may benefit from joint replacement, arthrodesis, or contracture release.

Previous
Next

Deterrence and Prevention

A number of medications can exacerbate psoriasis; therefore, avoidance of these agents may help to prevent or minimize flare-ups. Lithium and withdrawal from systemic corticosteroids are well known to cause disease flare-ups.

Other drugs that have been implicated include beta blockers, antimalarials (although, as previously mentioned, evidence suggests that hydroxychloroquine does not exacerbate skin lesions), and NSAIDs. If skin lesions worsen with an NSAID, switch to a different family of NSAID.

Prevention includes rest and exercise. Joint protection, including splints, braces, and other supports, may be helpful. No definitive prevention exists, because this is a chronic disease that can wax and wane.

Previous
 
 
Contributor Information and Disclosures
Author

Anwar Al Hammadi, MD, FRCPC Consultant and Head of Dermatology, Rashid Hospital, Dubai Health Authority; Clinical Associate Professor of Dermatology, Dubai Medical College; Clinical Assistant Professor of Dermatology, University of Sharjah, UAE

Anwar Al Hammadi, MD, FRCPC is a member of the following medical societies: American Academy of Dermatology, Royal College of Physicians and Surgeons of Canada, Canadian Dermatology Association, Skin Cancer Foundation

Disclosure: Nothing to disclose.

Coauthor(s)

Humeira Badsha, MD Consultant Rheumatologist, Dr Humeira Badsha Medical Center, UAE

Humeira Badsha, MD is a member of the following medical societies: American College of Rheumatology, Emirates Society for Rheumatology

Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa

Disclosure: Nothing to disclose.

Acknowledgements

Bruce Buehler, MD Professor, Department of Pediatrics and Genetics, Director RSA, University of Nebraska Medical Center

Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association

Disclosure: Nothing to disclose.

Denise I Campagnolo, MD, MS Director of Multiple Sclerosis Clinical Research and Staff Physiatrist, Barrow Neurology Clinics, St Joseph's Hospital and Medical Center; Investigator for Barrow Neurology Clinics; Director, NARCOMS Project for Consortium of MS Centers

Denise I Campagnolo, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, and Consortium of Multiple Sclerosis Centers

Disclosure: Teva Neuroscience Honoraria Speaking and teaching; Serono-Pfizer Honoraria Speaking and teaching; Genzyme Corporation Grant/research funds investigator; Biogen Idec Grant/research funds investigator; Genentech, Inc Grant/research funds investigator; Eli Lilly & Company Grant/research funds investigator; Novartis investigator; MSDx LLC Grant/research funds investigator; BioMS Technology Corp Grant/research funds investigator; Avanir Pharmaceuticals Grant/research funds investigator

Vinod Chandran, MBBS, MD, PhD Assistant Professor, Department of Medicine, Division of Rheumatology, University of Toronto Faculty of Medicine; Staff Physician, Division of Rheumatology, Toronto Western Hospital, Canada

Disclosure: Nothing to disclose.

Michael J Dans, MD, PhD Clinical Instructor, Department of Dermatology, University of California at San Francisco

Michael J Dans, MD, PhD is a member of the following medical societies: American Academy of Dermatology and American Medical Association

Disclosure: Nothing to disclose.

Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Patrick M Foye, MD Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School

Patrick M Foye, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, and International Spine Intervention Society

Disclosure: Nothing to disclose.

Dafna D Gladman, MD, FRCPC Professor of Medicine, University of Toronto Faculty of Medicine; Staff Physician, Division of Rheumatology, Toronto Western Hospital, Canada

Disclosure: Nothing to disclose.

Elliot Goldberg, MD Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine

Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, and American College of Rheumatology

Disclosure: Nothing to disclose.

Peter D Gorevic, MD, Professor and Chief, Division of Rheumatology, Mount Sinai School of Medicine

Disclosure: Nothing to disclose.

Jeffrey M Heftler, MD Interventional Physiatrist, Orthopaedic and Neurosurgical Specialists, Greenwich, CT

Jeffrey M Heftler, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation and International Spine Intervention Society

Disclosure: Nothing to disclose.

Alexa F Boer Kimball, MD, MPH Associate Professor of Dermatology, Harvard University School of Medicine; Vice Chair, Department of Dermatology, Massachusetts General Hospital; Director of Clinical Unit for Research Trials in Skin (CURTIS), Department of Dermatology, Massachusetts General Hospital

Alexa F Boer Kimball, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Kristine M Lohr, MD, MS Professor, Department of Internal Medicine, Center for the Advancement of Women's Health and Division of Rheumatology, Director, Rheumatology Training Program, University of Kentucky College of Medicine

Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians and American College of Rheumatology

Disclosure: Nothing to disclose.

Christen M Mowad, MD Associate Professor, Department of Dermatology, Geisinger Medical Center

Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Dermatological Association, Noah Worcester Dermatological Society, Pennsylvania Academy of Dermatology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Michael F Saulino, MD, PhD Assistant Professor, Department of Physical Medicine and Rehabilitation, MossRehab, Jefferson Medical College of Thomas Jefferson University

Michael F Saulino, MD, PhD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists, and Physiatric Association of Spine, Sports and Occupational Rehabilitation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Abby S Van Voorhees, MD Assistant Professor, Director of Psoriasis Services and Phototherapy Units, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania

Abby S Van Voorhees, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, National Psoriasis Foundation, Phi Beta Kappa, Sigma Xi, and Women's Dermatologic Society

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Merck Salary Management position; Abbott Honoraria Speaking and teaching; Amgen Honoraria Review panel membership; Centocor Honoraria Consulting; Leo Consulting; Merck None Other

Karolyn A Wanat, MD Resident Physician, Department of Dermatology, University of Pennsylvania School of Medicine

Karolyn A Wanat, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and American Medical Women's Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Rajesh R Yadav, MD Associate Professor, Section of Physical Medicine and Rehabilitation, MD Anderson Cancer Center, University of Texas Medical School at Houston

Rajesh R Yadav, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

References
  1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug. 54(8):2665-73. [Medline].

  2. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009 Mar. 60(3):402-11. [Medline].

  3. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008 May. 35(5):883-90. [Medline].

  4. Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009 May. 160(5):1040-7. [Medline].

  5. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr. 60(4):976-86. [Medline].

  6. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol. 2007 Dec. 157(6):1103-15. [Medline].

  7. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009. 11(1):214. [Medline]. [Full Text].

  8. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009 Jan-Feb. 22(1):40-55. [Medline].

  9. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases]. Rev Rhum Mal Osteoartic. 1987 Mar. 54(3):187-96. [Medline].

  10. Gmyrek R, Grossman ME, Rudin D, Scher R. SAPHO syndrome: report of three cases and review of the literature. Cutis. 1999 Oct. 64(4):253-8. [Medline].

  11. Fiocco U, Cozzi L, Chieco-Bianchi F, Rigon C, Vezzu M, Favero E, et al. Vascular changes in psoriatic knee joint synovitis. J Rheumatol. 2001 Nov. 28(11):2480-6. [Medline].

  12. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010 May. 34(3):J314-21. [Medline].

  13. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol. 2009 Feb. 5(2):83-91. [Medline]. [Full Text].

  14. Duffin KC, Chandran V, Gladman DD, Krueger GG, Elder JT, Rahman P. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008 Jul. 35(7):1449-53. [Medline]. [Full Text].

  15. Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugarajah S, Toloza SM, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis. 2009 May. 68(5):664-7. [Medline].

  16. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008 Mar 28. 4(3):e1000041. [Medline]. [Full Text].

  17. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009 Feb. 41(2):199-204. [Medline]. [Full Text].

  18. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet. 2010 Nov. 42(11):996-9. [Medline]. [Full Text].

  19. Sun LD, Cheng H, Wang ZX, Zhang AP, Wang PG, Xu JH, et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet. 2010 Nov. 42(11):1005-9. [Medline]. [Full Text].

  20. Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet. 2010 Nov. 42(11):991-5. [Medline]. [Full Text].

  21. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007 Feb. 80(2):273-90. [Medline]. [Full Text].

  22. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009 Jan-Feb. 22(1):56-60. [Medline].

  23. Huffmeier U, Lascorz J, Bohm B, Lohmann J, Wendler J, Mossner R, et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol. 2009 Feb. 129(2):355-8. [Medline].

  24. Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K, et al. Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford). 2002 May. 41(5):525-30. [Medline].

  25. Choy E. T cells in psoriatic arthritis. Curr Rheumatol Rep. 2007 Dec. 9(6):437-41. [Medline].

  26. Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, Young HS, et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis. 2008 May. 67(5):677-82. [Medline]. [Full Text].

  27. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004 Jun. 113(12):1664-75. [Medline]. [Full Text].

  28. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006 May. 78(5):827-51. [Medline]. [Full Text].

  29. Eder L, Pellett F, Chandran V, Shanmugarajah S, Gladman DD. HLA- B*27 and Cw*06 are risk alleles for psoriatic arthritis among psoriasis patients (abstract). Arthritis Rheum. 2010. 62(suppl 10):1974.

  30. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008 Feb. 144(2):200-7. [Medline].

  31. Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellett F, et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis. 2006 Jul. 65(7):919-23. [Medline]. [Full Text].

  32. Rahman P, Roslin NM, Pellett FJ, Lemire M, Greenwood CM, Beyene J, et al. High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis. Ann Rheum Dis. 2011 Apr. 70(4):690-4. [Medline].

  33. Pollock R, Chandran V, Barrett J, Eder L, Pellett F, Yao C, et al. Differential major histocompatibility complex class I chain-related A allele associations with skin and joint manifestations of psoriatic disease. Tissue Antigens. 2011 Jun. 77(6):554-61. [Medline].

  34. Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011 Jul. 29(7):615-24. [Medline].

  35. Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010 Nov. 42(11):985-90. [Medline]. [Full Text].

  36. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009 Feb 15. 61(2):233-9. [Medline]. [Full Text].

  37. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009 Feb. 36(2):361-7. [Medline]. [Full Text].

  38. Henes JC, Ziupa E, Eisfelder M, Adamczyk A, Knaudt B, Jacobs F, et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. Rheumatol Int. 2013 Oct 10. [Medline].

  39. Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis - a prospective cohort study. Arthritis Rheumatol. 2015 Nov 10. [Medline].

  40. Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013 Apr. 72(4):578-82. [Medline].

  41. Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol. 2010 Oct. 37(10):2141-4. [Medline].

  42. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011 Dec. 63(12):1729-35. [Medline].

  43. Torres T, Sales R, Vasconcelos C, Martins da Silva B, Selores M. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol. 2013 Oct 16. [Medline].

  44. Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct 7. [Medline].

  45. Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep. 64(9):2836-46. [Medline].

  46. Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Development and Validation of a Tool for Assessment of Nail Psoriasis Outcomes. Br J Dermatol. 2013 Oct 11. [Medline].

  47. Sanyal K, Stuart B. Osteopoikilosis: spotted bone disease in a patient with psoriatic arthritis. J Clin Rheumatol. 2010 Aug. 16(5):251. [Medline].

  48. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006 Apr. 65(4):478-81. [Medline]. [Full Text].

  49. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan. 71(1):4-12. [Medline].

  50. [Guideline] Coates LC, Tillett W, Chandler D, et al, on behalf of BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford). October 2013. 52(10):1754-7. [Medline]. [Full Text].

  51. Kelly JC. Psoriatic arthritis: guidelines for treatment with biologics. Medscape Medical News. November 4, 2013. [Full Text].

  52. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015 Oct. 373 (14):1329-39. [Medline].

  53. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19. 386 (9999):1137-46. [Medline].

  54. Brooks M. Ustekinumab approved for psoriatic arthritis in US, Europe. Medscape Medical News [serial online]. September 23, 2013. Medscape. Available at http://www.medscape.com/viewarticle/811496. Accessed: October 25, 2013.

  55. Brooks M. FDA approves certolizumab for psoriatic arthritis. Medscape Medical News. September 30, 2013. [Full Text].

  56. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Mar 4. [Medline].

  57. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012 Oct. 64(10):3156-67. [Medline].

  58. Brooks M. FDA Clears Apremilast (Otezla) for Psoriatic Arthritis. Medscape Medical News. Available at http://www.medscape.com/viewarticle/822396. Accessed: March 24, 2014.

  59. Otezla (apremilast) prescribing information [package insert]. Summit, NJ.: Celgene Corp. 2014. Available at [Full Text].

  60. Boggs W. Methotrexate Side Effects, Intolerance Common in Arthritis Patients. Medscape Medical News. Available at http://www.medscape.com/viewarticle/818646. Accessed: January 14, 2014.

  61. Bulatovic Calasan M, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013 Dec 18. 15(6):R217. [Medline].

  62. Schrader P, Mooser G, Peter RU, Puhl W. [Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil]. Z Rheumatol. 2002 Oct. 61(5):545-50. [Medline].

  63. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct. 52(10):3279-89. [Medline].

  64. Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008 Jul. 27(7):823-6. [Medline].

  65. Patel S, Veale D, FitzGerald O, McHugh NJ. Psoriatic arthritis--emerging concepts. Rheumatology (Oxford). 2001 Mar. 40(3):243-6. [Medline].

  66. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). 2009 May. 48(5):569-72. [Medline].

  67. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug. 64(8):1150-7. [Medline]. [Full Text].

  68. Helliwell PS, Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken). 2013 Oct 14. [Medline].

  69. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31. 382(9894):780-9. [Medline].

 
Previous
Next
 
Severe fixed flexion deformity of the interphalangeal joint.
Comparison between sites of involvements in both hands and feet in psoriatic arthritis and rheumatoid arthritis.
Psoriatic arthritis involving the distal phalangeal joint.
Swelling and deformity of the metacarpophalangeal and distal interphalangeal joints in a patient with psoriatic arthritis.
Psoriatic arthritis involving the distal phalangeal joint.
Psoriatic arthritis involving the distal phalangeal joint.
Asymmetrical arthritis pattern of psoriatic arthritis (fixed flexion deformity).
Arthritis mutilans, a typically psoriatic pattern of arthritis, which is associated with a characteristic "pencil-in-cup" radiographic appearance of digits.
Psoriatic arthritis involving the distal phalangeal joint.
Arthritis mutilans (ie, "pencil-in-cup" deformities).
Severe psoriatic arthritis showing involvement of the distal interphalangeal joints, distal flexion deformity, and telescoping of the left third, fourth, and fifth digits due to destruction of joint tissue.
Psoriatic arthritis showing nail changes, distal interphalangeal joint swelling, and sausage digits.
Left, typical appearance of psoriasis, with silvery scaling on a sharply marginated and reddened area of skin overlying the shin. Right, thimblelike pitting of the nail plate in a 56-year-old woman who had suffered from psoriasis for the previous 23 years. Nail pitting, transverse depressions, and subungual hyperkeratosis often occur in association with psoriatic disease of the distal interphalangeal joint. Courtesy of Ali Nawaz Khan, MBBS.
Lateral radiograph of the cervical spine shows syndesmophytes at the C2-3 and C6-7 levels, with zygapophyseal joint fusion. Courtesy of Bruce M. Rothschild, MD.
A 37-year-old man presents with a 1-year history of an erythematous and intensely pruritic rash at the bilateral soles of feet. He has mild dryness and fissuring at his hands, but no overlying scale, intense erythema, or itching like that at his feet. Diagnosis: Psoriatic arthritis (PsA), with palmoplantar pustulosis variant of psoriasis. Courtesy of Jason Kolfenbach, MD, and Kevin Deane, MD, Division of Rheumatology, University of Colorado Denver School of Medicine.
Table. Comparison of Expected Laboratory Values in Psoriatic Arthritis and Rheumatoid Arthritis
Laboratory Studies Psoriatic Arthritis Rheumatoid Arthritis
Erythrocyte sedimentation rate Elevated (< 100) Elevated (< 100)
Rheumatoid factor Negative Positive (85% of patients)
Antinuclear antibody Negative Positive (30% of patients)
C-reactive protein Elevated Elevated
Synovium WBC count 5000-15,000/µL, >50% polymorphonuclear leukocytes WBC count 2000/µL
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.